Measles, mumps, and rubella revaccination in children after completion of chemotherapy and hematopoietic stem cell transplantation: a single-center prospective efficacy and safety analysis.

[1]  B. Kuter,et al.  Prevention of measles, mumps and rubella: 40 years of global experience with M-M-RII , 2021, Human vaccines & immunotherapeutics.

[2]  M. Cheng,et al.  Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant. , 2021, Open forum infectious diseases.

[3]  H. Nakasone,et al.  Immunity and Vaccination Against Measles, Mumps, and Rubella in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients. , 2021, Transplantation and cellular therapy.

[4]  W. Klapper,et al.  Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial , 2020, Cancers.

[5]  Z. Ozdemir,et al.  Immunization status and re-immunization of childhood acute lymphoblastic leukemia survivors , 2020, Human vaccines & immunotherapeutics.

[6]  M. Pacenti,et al.  The Impact of Chemotherapy after Pediatric Malignancy on Humoral Immunity to Vaccine-Preventable Diseases , 2020, Mediterranean journal of hematology and infectious diseases.

[7]  K. Akashi,et al.  Safety and Seropositivity after Live Attenuated Vaccine in Adult Patients Receiving Hematopoietic Stem Cell Transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  A. Petrilli,et al.  Adherence and immune response to revaccination following hematopoietic stem cell transplantation at a pediatric onco‐hematology reference center , 2018, Transplant infectious disease : an official journal of the Transplantation Society.

[9]  Shaimaa M Kandil,et al.  Humoral immune response of childhood acute lymphoblastic leukemia survivors against the measles, mumps, and rubella vaccination , 2018, Hematology.

[10]  T. Klausen,et al.  Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia , 2018, Leukemia.

[11]  J. Laubach,et al.  Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation , 2018, Bone Marrow Transplantation.

[12]  M. Goswami,et al.  Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy , 2017, Journal of Translational Medicine.

[13]  F. Dhalla,et al.  Secondary immunodeficiency in lymphoproliferative malignancies , 2016, Hematological oncology.

[14]  F. Locatelli,et al.  Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000–2010 , 2016, Bone Marrow Transplantation.

[15]  G. Papanicolaou,et al.  Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  S. Esposito,et al.  Immunization of children with secondary immunodeficiency , 2015, Human vaccines & immunotherapeutics.

[17]  N. Rezaei,et al.  Assessment of Immune Response following Immunization with DTP/Td and MMR Vaccines in Children Treated for Acute Lymphoblastic Leukemia , 2014, Pediatric hematology and oncology.

[18]  K. Bochennek,et al.  Differential loss of humoral immunity against measles, mumps, rubella and varicella-zoster virus in children treated for cancer. , 2014, Vaccine.

[19]  M. Roivainen,et al.  Immunity after (re)vaccination of paediatric patients following haematopoietic stem cell transplantation , 2012, Acta paediatrica.

[20]  C. Pui,et al.  Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation , 2012, British journal of haematology.

[21]  Gustavo Baptista de Almeida Faro,et al.  Antibody responses to Hepatitis B and measles-mumps-rubella vaccines in children who received chemotherapy for acute lymphoblastic leukemia , 2012, Revista brasileira de hematologia e hemoterapia.

[22]  M. Josefson,et al.  Multivariate analysis of the relation between immune dysfunction and treatment intensity in children with acute lymphoblastic leukemia , 2011, Pediatric blood & cancer.

[23]  M. Tuncer,et al.  MEASLES, MUMPS, AND RUBELLA ANTIBODY STATUS AND RESPONSE TO IMMUNIZATION IN CHILDREN AFTER THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA , 2010, Pediatric hematology and oncology.

[24]  L. Aurpibul,et al.  Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  R. Borrow,et al.  Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  F. Fregonese,et al.  Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy , 2005, Cancer.

[27]  M. Giannaki,et al.  Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants , 2004, Bone Marrow Transplantation.

[28]  M. Burgess,et al.  Safety of early immunization against measles/mumps/rubella after bone marrow transplantation. , 2002, Blood.